SynthesisThe Cochrane database of systematic reviews2009
Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension.
Synthesis in The Cochrane database of systematic reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Dietary Supplementation for Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systematic Review.Nutrients · 2025Pooled it
- Nutraceuticals with a clinically detectable blood pressure-lowering effect: a review of available randomized clinical trials and their meta-analyses.British journal of clinical pharmacology · 2017Pooled it
- Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension.The Cochrane database of systematic reviews · 2016Pooled it
- Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2014Pooled it
- The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2019Trial
- Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2018Trial
- Combined Supplementation of Coenzyme QNutrients · 2022Review
- Review
- Coenzyme QAntioxidants (Basel, Switzerland) · 2021Review
- Effects of coenzyme Q10 on health-related quality of life, clinical disease activity and blood pressure in patients with mild to moderate ulcerative colitis: a randomized clinical trial.Medical journal of the Islamic Republic of Iran · 2021Article
- Coenzyme QAntioxidants (Basel, Switzerland) · 2020Review
- Nutrients and Nutraceuticals for the Management of High Normal Blood Pressure: An Evidence-Based Consensus Document.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2019Review
- Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem.Current cardiology reviews · 2018Review
- Adverse events associated with interactions with dietary and herbal supplements among inpatients.British journal of clinical pharmacology · 2017Article
- Interactions between dietary supplements in hospitalized patients.Internal and emergency medicine · 2016Article
- Coenzyme Q10 and Utility in Heart Failure: Just Another Supplement?Current heart failure reports · 2016Review
- Contribution of mitochondrial oxidative stress to hypertension.Current opinion in nephrology and hypertension · 2016Review
- Nutraceuticals and Blood Pressure Control: Results from Clinical Trials and Meta-Analyses.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2015Review
- The Vilification of Cholesterol (for Profit?).Integrative medicine (Encinitas, Calif.) · 2014Article
- Review
Corrections and comments
- Updated by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies have shown that coenzyme Q10 deficiency is associated with cardiovascular disease. Hypertension is a commonly measured surrogate marker for non-fatal and fatal cardiovascular endpoints such as heart attacks and strokes. Clinical trials have suggested that coenzyme Q10 supplementation can effectively lower blood pressure (BP).
objectivesTo determine the blood pressure lowering effect of coenzyme Q10 in primary hypertension. SEARCH STRATEGY: The Cochrane Central Register of Controlled Trials (2009 Issue 2), MEDLINE (1966 -May 2008), EMBASE (1982 - May 2008), and CINAHL (1970 - May 2008) as well as the reference lists of articles were searched for relevant clinical trials in any language. SELECTION CRITERIA: Double-blind, randomized, placebo-controlled parallel or crossover trials evaluating the BP lowering efficacy of coenzyme Q10 for a duration of at least 3 weeks in patients with primary hypertension. DATA COLLECTION AND ANALYSIS: The primary author independently assessed the risk of bias and extracted the data. The second author verified data extraction. MAIN
resultsThree clinical trials with a total of 96 participants were evaluated for the effects of coenzyme Q10 on blood pressure compared to placebo. Treatment with coenzyme Q10 in subjects with systolic BP (SBP) > 140 mmHg or diastolic BP (DBP) > 90 mmHg resulted in mean decreases in SBP of 11 mmHg (95% CI 8, 14) and DBP of 7 mmHg (95% CI 5, 8). AUTHORS'
conclusionsDue to the possible unreliability of some of the included studies, it is uncertain whether or not coenzyme Q10 reduces blood pressure in the long-term management of primary hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.